Dasatinib as a Network-modulating Tyrosine Kinase Inhibitor in Philadelphia Chromosome-positive Leukemias: Integration of BCR-ABL1, SRC, and MAPK Signaling
S. Vanitha, R. Kothai, B. Arul
DOI: 10.1177/22313354261472053Pages: 819-830
Dasatinib as a Network-modulating Tyrosine Kinase Inhibitor in Philadelphia Chromosome-positive Leukemias: Integration of BCR-ABL1, SRC, and MAPK Signaling
S. Vanitha, R. Kothai, B. Arul
DOI: 10.1177/22313354261472053Pages: 819-830